PharmaMar Group companies

PharmaMar is a leading oncology biopharmaceutical company dedicated to advancing cancer treatment through the discovery and development of innovative marine-derived medicines. The company’s vision is to provide new drugs from unexplored marine sources that address society’s need for new, more potent cancer therapies to improve patients’ lives. PharmaMar is the only company that has implemented a program focused on the discovery and development of drugs based on marine-derived agents.

Sylentis is a research company wholly owned by the Zeltia Group. Its objective is to discover and develop new therapies based on RNA interference (RNAi) technology, both for untreated diseases and for those with a treatment that needs to be improved.